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Park et al. are congratulated for their excellent results of the 
LUX-Lung 7 study. This phase IIb randomized-controlled 
trial directly compared afatinib with gefitinib as first-line 
treatment for epidermal growth factor receptor (EGFR)-
mutated metastatic non-small-cell lung cancer (NSCLC) (1). 
It is the first multi-center randomized trial comparing 
the two approved EGFR tyrosine-kinase inhibitors (TKI) 
in terms of efficacy and safety in a head-to-head manner. 
It was commenced in 2011 with 64 participating centers 
in 13 countries. All recruited and eligible patients must 
have stage IIIB (ineligible for curative intent surgery or 
local radiotherapy) or stage IV (recurrent or metastatic) 
pulmonary adenocarcinoma with documented either exon 
19 deletion or exon 21 L858R mutation as confirmed by 
the central laboratory. They were then randomized (1:1) 
to either afatinib 40 mg daily or gefitinib 250 mg daily 
stratified by EGFR mutational status (exon 19 deletion vs. 
L858R mutation) and baseline brain metastases (presence 
vs. absence). Those who were randomized to afatinib arm 
were allowed to escalate the dose of afatinib to 50 mg 
daily after 4 weeks of treatment if they did not experience 
rash, diarrhea, mucositis or any other drug-related adverse 
events of more than grade 1. The three co-primary study 
endpoints were progression-free survival (PFS), time-to-
treatment failure (TTF) and overall survival (OS) while the 
secondary endpoints were best objective response (OR), 
time to and duration of OR, disease control rate (DCR), 
duration of disease control, tumor shrinkage and change in 
quality of life scores.
A total of 319 patients were randomized to either afatinib 
(160 patients) or gefitinib (159 patients). After a median follow-
up duration of 27.3 months, the median PFS was 11.0 months 
[95% confidence interval (CI), 10.6–12.9 months] with afatinib 
and 10.9 months (95% CI, 9.1–11.5 months) with gefitinib 
[hazard ratio (HR) =0.73; 95% CI, 0.57–0.95; P=0.017] and 
TTF [median 13.7 months (95% CI, 11.9–15.0 months) 
with afatinib] compared to 11.5 (95% CI, 10.1–13.1 months) 
with gefitinib [HR =0.73; 95% CI, 0.58–0.92; P=0.0073]. In 
addition, OR was also significantly higher with afatinib (70%) 
as compared to gefitinib (56%, P=0.0083) though the DC rates 
were similar (91% vs. 87%). It was also translated to a longer 
median duration of response with afatinib (10.1 months) 
compared to gefitinib (8.4 months). With regards to the type 
of EGFR mutation, there was a trend of improved PFS with 
afatinib compared to gefitinib in patients who had either 
exon 19 deletion (12.7 vs. 11.0 months; HR =0.76; 95% CI, 
0.55–1.06; P=0.107) and L858R mutation (10.9 vs. 
10.8 months; HR =0.71; 95% CI, 0.47–1.06; P=0.087). Finally, 
OS data was yet to mature.
For the safety profiles, the frequency and severity of 
all-cause adverse events and ≥ grade 3 events were similar 
between the 2 arms. While diarrhea (13% vs. 1%) and 
rash (9% vs. 3%) were more commonly encountered in 
those who received afatinib, liver enzyme elevations were 
more prevalent with gefitinib. Apart from that, similar 
improvements in quality of life scores from baseline were 
seen in both arms.
Based on the results of LUX-Lung 7 trial, can we say 
afatinib, compared to the other two first-generation TKI 
namely gefitinib and erlotinib, is the better drug of choice as 
first-line treatment for metastatic EGFR-mutated NSCLC? 
All three drugs have been approved as first-line treatment 
based on the multicenter phase III randomized-controlled 
trials which demonstrated superb PFS, better ORs and 
more manageable toxicity profiles compared to platinum-
based doublet chemotherapy for EGFR-mutated advanced 
NSCLC (2-11). This together with icotinib, another 
EGFR TKI developed, manufactured, approved and widely 
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adopted in China based on its ICOGEN study in the 
same setting, are acceptable first-line therapies (12). No 
doubt, LUX-Lung 7 trial is the first showing the superior 
PFS with afatinib than gefitinib as first-line treatment for 
EGFR-mutated advanced NSCLC. This, in general, may 
represent the broader and more durable anti-tumor activity 
with this second-generation irreversible inhibitor against 
ErbB family of receptors (EGFR/ErbB1, HER2/ErbB2, 
ErbB3, and ErbB4) compared to the mere and reversible 
blockade of EGFR signaling with gefitinib and erlotinib 
(13,14). In addition, preclinical evidence suggested that 
afatinib also exhibits anti-tumor activity against T790M 
gatekeeper mutation (13,15). However, the results of this 
study should be interpreted with cautions. First and may be 
one of the most important criticisms against this study is 
its study design. It is still poorly understood why the study 
was conducted as a phase IIb rather than a phase III study, 
even though the authors explained that there might be 
insufficient data, at the time of trial concept and initiation, 
to construct a formal testing strategy with respect to the 
difference of effects between afatinib and gefitinib in this 
treatment setting. Secondly no hypotheses were generated 
for this study and the sample size estimation was merely 
based on controlling the width of confidence interval for 
the HR of PFS. The sample size required in this study may 
be underestimated, even though the sample size was later 
increased to 316 patients after study protocol amendment. 
The corollary was that the study may not be powered 
enough to draw any conclusion. Thirdly, the primary and 
secondary endpoints have been amended during the study 
periods by including OS as the co-primary endpoint and 
shifting disease control as secondary endpoint. The study 
team explained that this change was made to distinguish 
the primary endpoints from the less important secondary 
endpoints. In addition, the study protocol was also amended 
to mandate the balancing of recruitment in Asian versus 
non-Asian countries, leading to increase in sample size. 
Notwithstanding, these modifications still could not 
change the setting of this study as a phase IIb instead of 
phase III study and might in fact impede the contemplation 
of a subsequent phase III trial. In addition, the nuance of 
difference in PFS between afatinib and gefitinib (only about 
3 days) has to be balanced at the expense of more diarrhea 
and acneiform rash with afatinib. Finally, the study did 
not clearly elucidate if there was any statistical difference 
in quality of life scores between afatinib and gefitinib. Of 
note, though the PFS with afatinib (11.0 months) in LUX-
Lung 7 trial fully concurred with those reported in LUX-
Lung 3 (11.1 months) and LUX-Lung 6 (11.0 months) 
(10,11), this is not probably the best when compared to PFS 
with erlotinib, another 1st generation inhibitor erlotinib in 
OPTIMAL study (13.1 months) (5). One interesting finding 
from LUX-Lung 7 trial was that the two PFS curves started 
to divide at 12 months after commencement the respective 
TKI. We are expecting to see if there is OS difference 
between the two arms after longer follow-up.
In summary, afatinib was found to have significantly 
longer PFS compared with gefitinib, albeit the modest 
absolute difference. It is still immature to conclude 
that afatinib is superior to gefitinib due to the inherent 
limitations of the study design and the lack of longer follow-
up to observe the impact on OS. Up till now, gefitinib, 
erlotinib and afatinib are equally acceptable first-line 
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